Argireline in Treatment of Periorbital Wrinkles
Launched by MAHIDOL UNIVERSITY · Jun 23, 2011
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
Argireline has mechanism of action that significantly inhibited neurotransmitter release with a potency similar to that of BoNTA. Inhibition of neurotransmitter release was due to the interference of the hexapeptide with the formation and/or stability of SNARE complex. Notably, this peptide did not exhibit in vivo oral toxicity nor primary irritation at high doses. These findings demonstrate that Argireline is a anti-wrinkle peptide that emulates the action of currently used BoNTs.
In vivo study, Topical Argireline 10% is applied on lateral preorbital area twice daily for 30 days. The resu...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • healthy woman at 35-45 years old
- • Presence of periorbital wrinkles
- Exclusion Criteria:
- • Pregnancy
- • Nursing
- • Keloids /scar at periorbital area
- • pre-treatment with topical periorbital products within 1 month
- • Botulinum toxin A injection,facial plastic surgery within 1 year
- • Allergic to active ingredients including acetyl hexapeptide-3 Argireline®, sodium hyaluronate,adenosine,arbutin,fucus vesiculosus)
About Mahidol University
Mahidol University, a premier institution in Thailand, is dedicated to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the university leverages its extensive expertise in medical and health sciences to facilitate rigorous scientific investigations aimed at improving patient care and public health outcomes. With a commitment to ethical practices and collaboration, Mahidol University fosters multidisciplinary approaches, engaging a diverse array of researchers and healthcare professionals to drive meaningful advancements in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkoknoi, Bangkok, Thailand
Patients applied
Trial Officials
Supenya varothai, M.D.
Principal Investigator
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials